Review



tumor cell derived exosomes  (Exosome Diagnostics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Exosome Diagnostics tumor cell derived exosomes
    Tumor Cell Derived Exosomes, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+cell+derived+exosomes/cell+derived+exosomes+myeloma/pm41950246-262-101-74
    Average 86 stars, based on 1 article reviews
    tumor cell derived exosomes - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    Activity Assay:

    Article Title: Engineering exosomes with iRGD for targeted RNAi therapy against pancreatic cancer mediated by long non-coding RNA PLBD1-AS1.
    Article Snippet: .. These data suggest that exosomes can effectively deliver siPLBD1-AS1 into target cells and exert biological effects, with iRGD further improving cellular uptake and enhancing their anticancer activity. analysis of α-SMA, VIM, FAP, and β-actin in PSCs after treatment with tumor cell-derived exosomes (n = 3). (C) ELISA of IL-6, MCP-1, and FN levels in the supernatant of PSCs incubated with tumor cell-derived exosomes (n = 3). (E) ECAR and OCR measurements of PSCs following exosome treatment (n = 3). (F) Intracellular and extracellular lactate levels in PSCs after exosome incubation (n = 3). (G) ALDOA enzyme activity in PSCs treated with tumor cell-derived exosomes (n = 3). (H) Western blot analysis of α-SMA, VIM, FAP, and GAPDH in PSCs incubated with exosomes under low glucose, 2-DG, or ALDOA knockdown conditions (n = 3). (I) ELISA of IL-6, MCP-1, and FN in the supernatant of PSCs treated with exosomes under low glucose, 2-DG, or ALDOA knockdown (n = 3). ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Engineering exosomes with iRGD for targeted RNAi therapy against pancreatic cancer mediated by long non-coding RNA PLBD1-AS1.
    Article Snippet: .. These data suggest that exosomes can effectively deliver siPLBD1-AS1 into target cells and exert biological effects, with iRGD further improving cellular uptake and enhancing their anticancer activity. analysis of α-SMA, VIM, FAP, and β-actin in PSCs after treatment with tumor cell-derived exosomes (n = 3). (C) ELISA of IL-6, MCP-1, and FN levels in the supernatant of PSCs incubated with tumor cell-derived exosomes (n = 3). (E) ECAR and OCR measurements of PSCs following exosome treatment (n = 3). (F) Intracellular and extracellular lactate levels in PSCs after exosome incubation (n = 3). (G) ALDOA enzyme activity in PSCs treated with tumor cell-derived exosomes (n = 3). (H) Western blot analysis of α-SMA, VIM, FAP, and GAPDH in PSCs incubated with exosomes under low glucose, 2-DG, or ALDOA knockdown conditions (n = 3). (I) ELISA of IL-6, MCP-1, and FN in the supernatant of PSCs treated with exosomes under low glucose, 2-DG, or ALDOA knockdown (n = 3). ..

    Incubation:

    Article Title: Engineering exosomes with iRGD for targeted RNAi therapy against pancreatic cancer mediated by long non-coding RNA PLBD1-AS1.
    Article Snippet: .. These data suggest that exosomes can effectively deliver siPLBD1-AS1 into target cells and exert biological effects, with iRGD further improving cellular uptake and enhancing their anticancer activity. analysis of α-SMA, VIM, FAP, and β-actin in PSCs after treatment with tumor cell-derived exosomes (n = 3). (C) ELISA of IL-6, MCP-1, and FN levels in the supernatant of PSCs incubated with tumor cell-derived exosomes (n = 3). (E) ECAR and OCR measurements of PSCs following exosome treatment (n = 3). (F) Intracellular and extracellular lactate levels in PSCs after exosome incubation (n = 3). (G) ALDOA enzyme activity in PSCs treated with tumor cell-derived exosomes (n = 3). (H) Western blot analysis of α-SMA, VIM, FAP, and GAPDH in PSCs incubated with exosomes under low glucose, 2-DG, or ALDOA knockdown conditions (n = 3). (I) ELISA of IL-6, MCP-1, and FN in the supernatant of PSCs treated with exosomes under low glucose, 2-DG, or ALDOA knockdown (n = 3). ..

    Western Blot:

    Article Title: Engineering exosomes with iRGD for targeted RNAi therapy against pancreatic cancer mediated by long non-coding RNA PLBD1-AS1.
    Article Snippet: .. These data suggest that exosomes can effectively deliver siPLBD1-AS1 into target cells and exert biological effects, with iRGD further improving cellular uptake and enhancing their anticancer activity. analysis of α-SMA, VIM, FAP, and β-actin in PSCs after treatment with tumor cell-derived exosomes (n = 3). (C) ELISA of IL-6, MCP-1, and FN levels in the supernatant of PSCs incubated with tumor cell-derived exosomes (n = 3). (E) ECAR and OCR measurements of PSCs following exosome treatment (n = 3). (F) Intracellular and extracellular lactate levels in PSCs after exosome incubation (n = 3). (G) ALDOA enzyme activity in PSCs treated with tumor cell-derived exosomes (n = 3). (H) Western blot analysis of α-SMA, VIM, FAP, and GAPDH in PSCs incubated with exosomes under low glucose, 2-DG, or ALDOA knockdown conditions (n = 3). (I) ELISA of IL-6, MCP-1, and FN in the supernatant of PSCs treated with exosomes under low glucose, 2-DG, or ALDOA knockdown (n = 3). ..

    Knockdown:

    Article Title: Engineering exosomes with iRGD for targeted RNAi therapy against pancreatic cancer mediated by long non-coding RNA PLBD1-AS1.
    Article Snippet: .. These data suggest that exosomes can effectively deliver siPLBD1-AS1 into target cells and exert biological effects, with iRGD further improving cellular uptake and enhancing their anticancer activity. analysis of α-SMA, VIM, FAP, and β-actin in PSCs after treatment with tumor cell-derived exosomes (n = 3). (C) ELISA of IL-6, MCP-1, and FN levels in the supernatant of PSCs incubated with tumor cell-derived exosomes (n = 3). (E) ECAR and OCR measurements of PSCs following exosome treatment (n = 3). (F) Intracellular and extracellular lactate levels in PSCs after exosome incubation (n = 3). (G) ALDOA enzyme activity in PSCs treated with tumor cell-derived exosomes (n = 3). (H) Western blot analysis of α-SMA, VIM, FAP, and GAPDH in PSCs incubated with exosomes under low glucose, 2-DG, or ALDOA knockdown conditions (n = 3). (I) ELISA of IL-6, MCP-1, and FN in the supernatant of PSCs treated with exosomes under low glucose, 2-DG, or ALDOA knockdown (n = 3). ..



    Similar Products

    tumor cell derived exosomes  (Exosome Diagnostics)
    86
    Exosome Diagnostics tumor cell derived exosomes
    Tumor Cell Derived Exosomes, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+cell+derived+exosomes/cell+derived+exosomes+myeloma/pm41950246-262-101-74
    Average 86 stars, based on 1 article reviews
    tumor cell derived exosomes - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    press dendritic cell derived exosomes dex tumor antigens non small cell lung cancer phase i ii 134 exosome based vaccines  (Exosome Diagnostics)
    86
    Exosome Diagnostics press dendritic cell derived exosomes dex tumor antigens non small cell lung cancer phase i ii 134 exosome based vaccines
    Press Dendritic Cell Derived Exosomes Dex Tumor Antigens Non Small Cell Lung Cancer Phase I Ii 134 Exosome Based Vaccines, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+cell+derived+exosomes/breast+cancer+dna+electrochemical+g+homogeneous+nanohydrogel+pb2+quadruplex+staging/pm41817789-275-9-24
    Average 86 stars, based on 1 article reviews
    press dendritic cell derived exosomes dex tumor antigens non small cell lung cancer phase i ii 134 exosome based vaccines - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    cancer cell derived exosomes cc exos  (Exosome Diagnostics)
    86
    Exosome Diagnostics cancer cell derived exosomes cc exos
    Cancer Cell Derived Exosomes Cc Exos, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+cell+derived+exosomes/bmmscs+derived+exos+exosome+gelma+gelma+hydrogel+loaded/pm41242353-391-9-0
    Average 86 stars, based on 1 article reviews
    cancer cell derived exosomes cc exos - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    genetically engineered tumor cell-derived exosomes  (Morishita Jintan)
    90
    Morishita Jintan genetically engineered tumor cell-derived exosomes
    Genetically Engineered Tumor Cell Derived Exosomes, supplied by Morishita Jintan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+cell+derived+exosomes/genetically+engineered+tumor+cell+derived+exosomes/10__1016_slash_j__vesic__2022__100012-291-17-0
    Average 90 stars, based on 1 article reviews
    genetically engineered tumor cell-derived exosomes - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    genetically engineered tumor cell-derived exosomes with immunostimulatorycpg dna  (Morishita Jintan)
    90
    Morishita Jintan genetically engineered tumor cell-derived exosomes with immunostimulatorycpg dna
    a Trends of publications and major discoveries regarding <t>exosomes.</t> b Publication trends <t>in</t> <t>Exosome</t> research field from 1989 to 2019 (red dotted line: the prediction trends, blue line: the original trends). (Adapted from Reference and respectively under open access article distributed under the Creative Commons Attribution License)
    Genetically Engineered Tumor Cell Derived Exosomes With Immunostimulatorycpg Dna, supplied by Morishita Jintan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+cell+derived+exosomes/genetically+engineered+tumor+cell+derived+exosomes+with+immunostimulatorycpg+dna/pmc08716303-29-12-17
    Average 90 stars, based on 1 article reviews
    genetically engineered tumor cell-derived exosomes with immunostimulatorycpg dna - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a Trends of publications and major discoveries regarding exosomes. b Publication trends in Exosome research field from 1989 to 2019 (red dotted line: the prediction trends, blue line: the original trends). (Adapted from Reference and respectively under open access article distributed under the Creative Commons Attribution License)

    Journal: Journal of Nanobiotechnology

    Article Title: A systematic review on the modifications of extracellular vesicles: a revolutionized tool of nano-biotechnology

    doi: 10.1186/s12951-021-01219-2

    Figure Lengend Snippet: a Trends of publications and major discoveries regarding exosomes. b Publication trends in Exosome research field from 1989 to 2019 (red dotted line: the prediction trends, blue line: the original trends). (Adapted from Reference and respectively under open access article distributed under the Creative Commons Attribution License)

    Article Snippet: 30 , Exosome-based tumor antigens adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatoryCpG DNA , Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y , Japan , 2016 , Genetic Engineering , [ ] .

    Techniques:

    Summary of characteristics of included studies

    Journal: Journal of Nanobiotechnology

    Article Title: A systematic review on the modifications of extracellular vesicles: a revolutionized tool of nano-biotechnology

    doi: 10.1186/s12951-021-01219-2

    Figure Lengend Snippet: Summary of characteristics of included studies

    Article Snippet: 30 , Exosome-based tumor antigens adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatoryCpG DNA , Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y , Japan , 2016 , Genetic Engineering , [ ] .

    Techniques: In Situ, Fluorescence, Labeling, In Vitro, In Vivo, Synthesized, Conjugation Assay, Cell Culture, Enzyme-linked Immunosorbent Assay, Surround Optical-fiber Immunoassay, Derivative Assay, Functional Assay, Small Interfering RNA, Transfection, CRISPR, Electroporation, Construct, Activity Assay, Sonication, Injection, Binding Assay

    Modifications of extracellular vesicles and its role in nano-biotechnology

    Journal: Journal of Nanobiotechnology

    Article Title: A systematic review on the modifications of extracellular vesicles: a revolutionized tool of nano-biotechnology

    doi: 10.1186/s12951-021-01219-2

    Figure Lengend Snippet: Modifications of extracellular vesicles and its role in nano-biotechnology

    Article Snippet: 30 , Exosome-based tumor antigens adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatoryCpG DNA , Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y , Japan , 2016 , Genetic Engineering , [ ] .

    Techniques: Modification, In Vivo, Sonication, Electroporation, Inhibition, Activation Assay